[CDTX] Cidara Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11 Change: 0.8 (7.84%)
Ext. hours: Change: 0 (0%)

chart CDTX

Refresh chart

Strongest Trends Summary For CDTX

CDTX is in the medium-term up 28% in 7 months. In the long-term down -90% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities41.41 M Cash From Investing Activities-30 K Cash From Operating Activities-6.05 M Gross Profit
Net Profit-6.74 M Operating Profit-6.73 M Total Assets60.78 M Total Current Assets58.4 M
Total Current Liabilities3.81 M Total Debt Total Liabilities3.84 M Total Revenue
Technical Data
High 52 week4.13 Low 52 week1.25 Last close2.26 Last change-2.16%
RSI54.12 Average true range0.17 Beta0.85 Volume27 K
Simple moving average 20 days1.85% Simple moving average 50 days10.89% Simple moving average 200 days10.59%
Performance Data
Performance Week-1.31% Performance Month19.26% Performance Quart60.28% Performance Half18.95%
Performance Year-38.59% Performance Year-to-date-3.83% Volatility daily3.41% Volatility weekly7.62%
Volatility monthly15.62% Volatility yearly54.11% Relative Volume259.89% Average Volume482.07 K
New High New Low

News

2020-05-20 08:45:42 | Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

2020-05-13 18:05:10 | Cidara Therapeutics CDTX Reports Q1 Loss, Misses Revenue Estimates

2020-05-13 16:53:02 | Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results

2020-05-05 16:30:10 | Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2020-05-05 12:00:04 | What Makes Cidara Therapeutics CDTX a New Strong Buy Stock

2020-04-28 08:00:10 | Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference

2020-04-07 08:00:10 | Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

2020-03-31 12:00:04 | What Makes Cidara Therapeutics CDTX a New Buy Stock

2020-03-04 07:30:12 | Cidara Therapeutics CDTX Reports Q4 Loss, Misses Revenue Estimates

2020-03-04 05:55:10 | Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-27 12:00:05 | Cidara Therapeutics CDTX Upgraded to Buy: What Does It Mean for the Stock?

2020-02-18 08:00:10 | Cidara Therapeutics to Present at Transplantation & Cellular Therapy TCT and Mycology 2020 Medical Conferences

2020-02-12 17:30:25 | Cidara Therapeutics Announces Closing of Rights Offering

2020-02-11 06:25:57 | Some Cidara Therapeutics NASDAQ:CDTX Shareholders Have Taken A Painful 74% Share Price Drop

2020-01-22 07:55:10 | Cidara Therapeutics Announces Commencement of Rights Offering

2020-01-16 07:02:12 | New Strong Sell Stocks for January 16th

2020-01-10 08:00:10 | Cidara Therapeutics Announces Proposed Rights Offering

2019-12-20 10:22:07 | Hedge Funds Bailed Out Of Cidara Therapeutics Inc CDTX Too Early

2019-12-13 05:38:49 | Should You Take Comfort From Insider Transactions At Cidara Therapeutics, Inc. NASDAQ:CDTX?

2019-12-03 08:00:10 | Cidara Therapeutics to Present at Two Upcoming Medical Conferences

2019-11-18 08:00:00 | Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year

2019-11-07 21:17:06 | Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

2019-11-05 08:00:00 | Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

2019-10-06 20:22:34 | Weekly CFO Buys Highlight

2019-10-03 10:22:55 | Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

2019-10-01 10:07:00 | Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

2019-09-16 16:05:00 | Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

2019-09-04 14:37:34 | Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

2019-09-04 12:07:41 | A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

2019-09-03 12:31:21 | Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT

2019-09-03 06:41:00 | Cidara Therapeutics's stock rockets after commercialization deal with a potential value of up to $568 million

2019-08-21 08:00:00 | Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference

2019-08-08 16:07:49 | Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results

2019-08-07 07:30:00 | Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

2019-07-29 07:00:00 | Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin

2019-07-01 09:13:00 | X-Biotix Therapeutics Joins Antimicrobials Working Group

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

2019-06-19 13:16:12 | Imagine Owning Cidara Therapeutics NASDAQ:CDTX And Trying To Stomach The 85% Share Price Drop

2019-06-07 09:27:00 | Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

2019-06-05 08:00:00 | Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019

2019-05-22 09:00:01 | What Makes Cidara Therapeutics CDTX a New Buy Stock

2019-05-09 19:54:23 | Cidara Therapeutics: 1Q Earnings Snapshot

2019-05-09 16:13:53 | Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results

2019-04-16 08:00:00 | Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019

2019-04-15 08:00:00 | Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza Antiviral Program

2019-04-12 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-03 16:04:00 | Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

2019-03-26 08:00:00 | Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-03-07 08:00:00 | Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

2019-03-04 12:19:18 | Have Insiders Been Buying Cidara Therapeutics, Inc. NASDAQ:CDTX Shares?